14 October 2014
Highlights in Medicinal Chemistry
Organised by:
SCI’s Fine Chemicals Group
SCI, London, UK
Registration Closed
This event is no longer available for registration.
Share this event
Synopsis
This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.Attendees
This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.
Programme
Day 1
- 09:20
- Registration and refreshments
- 09:50
- Welcome and introduction
- 09:55
- Data mining ChEMBL for new leads against new targets
Dr John Overington, European Molecular Biology Laboratory - European Bioinformatics Institute (EMBL-EBI) - 10:35
- Fatty Acid Synthase (FAS) triazolone inhibitors, good potency & properties but a metabolic liability?
Dr Cliff Jones, AstraZeneca - 11:00
- Stabilised receptor enabled structure based drug design: Identification of dual orexin receptor antagonists (DORAs)
Dr Sarah Aves, Heptares - 11:25
- Refreshments
- 11:45
- Squaramides: physical properties, synthesis & application in medicinal chemistry
Dr Ian Storer, Pfizer - 12:10
- Fragment-based drug discovery for a protein-protein interaction target: from mM fragments to nM dual antagonist of XIAP and cIAP1
Dr Emiliano Tamanini, Astex - 12:35
- The monster mas agonist - revealing the beauty in the beast
Dr Simon Peace, GlaxoSmithKline - 13:00
- Lunch and exhibition
- 14:00
- A tale of two MEK inhibitors - the difficulty of preclinical differentiation
Dr Henrik Moebitz, Novartis - 14:25
- Structure-guided design of BH3-mimetic Mcl-1 inhibitors
Dr Jonathan Hollick, Evotec - 14:50
- Dr Lilian Alcaraz, Argenta
- 15:30
- Refreshments
- 15:50
- Designing membrane permeable 'large' molecule NS5A inhibitors
Dr David Pryde, Pfizer - 16:15
- Discovery of ATR selective inhibitors for the treatment of cancer
Dr Joanne Pinder, Vertex - 16:40
- Matched triplicates in the optimisation of a novel series of glucokinase activators
Dr Mike Waring, AstraZeneca - 17:20
- Closing remarks
- 17:25
- Wine reception
Venue and Contact
SCI
14/15 Belgrave Square
London SW1X 8PS
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
Fees
Early Bird Rate - before 29 August 2014
| One-Day Fee | Two-Day Fee* | ||
| SCI Member | GB£100 | SCI Member | GB£175 |
| SCI Student Member | GB£35 | SCI Student Member | GB£60 |
| Non-Member | GB£130 | Non-Member | GB£235 |
Standard Rate - after 29 August 2014
| One-Day Fee | Two-Day Fee* | ||
| SCI Member | GB£115 | SCI Member | GB£205 |
| SCI Student Member | GB£40 | SCI Student Member | GB£70 |
| Non-Member | GB£150 | Non-Member | GB£270 |
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
CPD Info
SCI Members attending this meeting are able to claim CPD points.
Sponsors
Third Tier Sponsor/Exhibitors
Additional Info
Exhibition and Sponsorship
An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.